Patent application number | Description | Published |
20130216565 | VACCINES BASED ON PEPTIDES OF THE COMPLEMENT PROTEIN C5A - The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRAN-ISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22). | 08-22-2013 |
20140234877 | METHOD FOR DETECTING A BETA-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE - Disclosed is a method for detecting Aβ-specific antibodies in a biological sample comprising the following steps:—contacting the sample with Aβ-aggregates or with particles comprising Aβ-aggregate like surfaces and allowing the Aβ-specific antibodies to bind to the Aβ-aggregates, and -detecting the Aβ-specific antibodies bound to the Aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting FACS. | 08-21-2014 |
20140242727 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE (AD) - Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein Aβ-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with Aβ-aggregates or with particles having Aβ-aggregate like surfaces and allowing the Aβ-specific antibodies to bind to the Aβ-aggregates, and —detecting the Aβ-specific antibodies bound to the Aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of Aβ-specific antibodies detected is compared with the amount in a sample of known AD status. | 08-28-2014 |
20150071951 | VACCINE - The present invention relates to a vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein said at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9). | 03-12-2015 |